文献速递免疫规划

角鲨烯油乳化MPL-A与抗CD200/CD300a抗体佐剂的全灭活利什曼原虫疫苗可对杜氏利什曼原虫提供持久免疫

A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites.
PubMed 文献 · Vaccine · 2024-09-16

研究评估标准化全灭活利什曼原虫疫苗(Leishvacc)单独或联合抗CD200和抗CD300a抗体、以及MPL-SE角鲨烯乳剂佐剂后,恢复树突状细胞抗原呈递能力、CD4+T细胞效应功能及抗杜氏利什曼原虫保护的效果。抗体佐剂疫苗(无论是否加MPL-SE)增强CD11c+树突状细胞CD80、CD86、MHC-I、MHC-II及胞内IL-12表达,增加产IL-2、IFN-γ、IL-23、IL-12的CD4+T细胞,显著增加CD4+中枢记忆T细胞数量及 longevity,并显著降低寄生虫血症、脾肿大、肝肿大及肝肉芽肿数量。

要点

  • 抗体佐剂疫苗增强CD11c+树突状细胞CD80、CD86、MHC-I、MHC-II及胞内IL-12表达,优于非佐剂疫苗。
  • 抗体/MPL-SE佐剂疫苗增加产IL-2、IFN-γ、IL-23、IL-12的CD4+T细胞。
  • 抗体佐剂疫苗(无论是否加MPL-SE)显著增加CD4+中枢记忆T细胞数量及 longevity,并显著降低寄生虫血症、脾肿大、肝肿大及肝肉芽肿数量。

核心结论

  • 研究提示该免疫预防策略不仅满足安全性标准,还提供强免疫原性反应,在控制寄生虫方面有显著潜力。
  • 作者指出需进一步深入研究以确定其诱导持久免疫的能力。

研究设计与样本

  • 动物实验:评估标准化全灭活利什曼原虫疫苗(Leishvacc)单独或联合抗CD200和抗CD300a抗体、以及MPL-SE角鲨烯乳剂佐剂的效果。
  • 检测指标包括CD11c+树突状细胞表面CD80、CD86、MHC-I、MHC-II及胞内IL-12,CD4+T细胞增殖及产IL-2、IFN-γ、IL-23、IL-12能力,CD4+中枢记忆T细胞数量及 longevity,以及寄生虫生长、寄生虫血症、脾肿大、肝肿大和肝肉芽肿数量。

主要发现

  • 抗体佐剂疫苗(单独或加MPL-SE)组CD11c+树突状细胞对利什曼原虫抗原的CD80、CD86、MHC-I、MHC-II表面受体及胞内IL-12表达增强,优于非佐剂疫苗组。
  • 抗体/MPL-SE佐剂疫苗组产IL-2、IFN-γ、IL-23、IL-12的CD4+T细胞增多,提示该策略帮助抗原活化CD4+T细胞获得产促炎细胞因子能力。
  • 抗体佐剂疫苗(单独或加MPL-SE)组CD4+中枢记忆T细胞数量及其 longevity 显著增强。
  • 抗体佐剂疫苗(单独或加MPL-SE)组通过限制强毒力寄生虫生长表现出优异保护,与显著降低的寄生虫血症、脾肿大、肝肿大及较少的肝肉芽肿数量相关。

局限性

  • 作者指出需进一步深入研究以确定其诱导持久免疫的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antigenic inefficacy to induce robust immune responses and durable memory are major causes of constantly failing prophylactic approaches in leishmaniasis. Here, we determine the potential of a standardized whole-killed Leishmania vaccine (Leishvacc) adjuvanted with anti-CD200 and anti-CD300a antibodies, either alone or with monophosphoryl lipid A (MPL-SE) emulsified in squalene oil, in restoring the compromised antigen presenting abilities of dendritic cells (DCs), effector properties of CD4+T cells and providing protection against Leishmania donovani parasites. In animals vaccinated with antibodies adjuvanted vaccines, either alone or with MPL-SE, the antigen presenting abilities of CD11c+ DCs against Leishmania antigens, measured in terms of CD80, CD86, MHC-I, and MHC-II surface receptors and intracellular IL-12 were found enhanced than non-adjuvanted vaccine. We observed more proliferative and pro-inflammatory cytokines i.e. IL-2, IFN-γ, IL-23, and IL-12 producing CD4+T cells in antibodies/MPL-SE adjuvanted vaccinated animals further suggesting that this approach helps antigen activated CD4+T cells to acquire pro-inflammatory cytokines producing abilities. In antibodies, either alone or with MPL-SE, vaccinated animals, the number of CD4+ central memory T cells and their longevity were found significantly enhanced that further evidenced the impact of this vaccination approach in inducing long term protective immunity. The animals, receiving antibodies adjuvanted vaccines, either alone or with MPL-SE, exhibited excellent protection against virulent parasites by restricting their growth, which correlated with the significantly reduced parasitemia, splenomegaly, and hepatomegaly, along with fewer numbers of liver granulomas. Our findings provide an insight to a new immunoprophylactic approach against visceral leishmaniasis, which not only satisfies the safety criteria, but also provides a robust immunogenic response with remarkable potential for parasites control. However, further in-depth investigations are needed to ascertain its ability in inducing long-lasting immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mahapatra B, Singh A, Banerjee A, et al. A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites. Vaccine. 2024. PMID: 39288578. doi:10.1016/j.vaccine.2024.126373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。